ARMO BioSciences

Eli Lilly

Biotech

Lilly cans pancreatic cancer program for Armo buyout drug

Eli Lilly is canning the lead program for the crown jewel of its $1.6 billion Armo buyout after the drug put up a poor showing in pancreatic cancer.

Amirah Al Idrus Oct 23, 2019 9:20am

Eli Lilly

Lilly's Armo buyout drug a bust in pancreatic cancer

Oct 16, 2019 7:28am

person handwriting a letter

Cel-Sci CEO paints 'promising future' in letter to shareholders

Aug 22, 2018 8:09am

Eli Lilly

Lilly boosts immuno-oncology pipeline with $1.6B Armo buy

May 10, 2018 10:38am

Dollars

Armo taps Celgene, GV for $67M to fuel late-phase I-O R&D

Aug 30, 2017 9:09am